On June 20, 2021 Natallie Rocha of the San Diego Business Journal talked with Onchilles reported $7 million Series A financing (Press release, Onchilles Pharma, JUN 20, 2021, View Source [SID1234584539]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"The infusion of funding will bolster Onchilles’ development of a new cancer treatment and finding the Achilles heel of oncology as the biotech’s name suggests," said Court R. Turner, co-founder and executive chair of Onchilles Pharma.

Turner has more than 20 years of experience growing companies from founding to fundraising and acquisition. Some of his previous ventures include serving as founding CEO of Synthorx, Inc. — which was acquired by Sanofi — Cellular Approaches, Inc. and RQx Pharmaceuticals which was acquired by Genentech.

"If you’re going to start an early-stage company and you need early-stage, talent and facilities and capital, all of those kinds of things — San Diego is as good a place as anywhere in the country to do that," Turner said.